opdivo
BMS’ Opdivo to finally be made available to lung cancer patients in the UK
September 20, 2017Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, biotech, drugs, opdivo, pharma, pharmaceutical
It is two and a half years since patients with lung cancer in the US were able to receive Bristol-Myers …
BMS’ Opdivo gets a potential first-line boost in kidney cancer
September 8, 2017Medical Communications, Research and Development Bristol-Myers Squibb, biotech, drugs, opdivo, pharma, pharmaceutical
Bristol-Myers Squibb has announced results from a Phase 3 trial showing that patients treated with Opdivo alongside Yervoy in patients …
BMS hit by clinical trial hold from FDA
September 7, 2017Medical Communications, Sales and Marketing Bristol-Myers Squibb, biotech, drugs, immunotherapy, opdivo, pharma, pharmaceutical
The FDA has placed a partial hold on clinical trials involving Bristol-Myers Squibb’s immunotherapy treatment, Opdivo, when used in combination …
BMS left red-faced as Opdivo+Yervoy fails to beat rival Pfizer drug in kidney cancer
August 16, 2017Research and Development BMS, Kidney cancer, Yervoy, life sciences, opdivo, pharma, pharmaceutical
Bristol-Myers Squibb has been left somewhat red-faced after its combination of Opdivo (nivolumab) and Yervoy (ipilimumab) failed to show any …
SMC reverses decision on Opdivo for kidney cancer
June 12, 2017Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, SMC, opdivo
The Scottish Medicines Consortium (SMC) has performed a U-turn on its decision regarding Opdivo (nivolumab), and will now allow patients …
England “really is not a good place” to get cancer, BMS UK General Manager says
April 24, 2017Medical Communications, Research and Development, Sales and Marketing BMS, NICE, opdivo
Bristol-Myers Squibb’s UK General Manager Ben Hickey has slammed NICE over its assessment criteria and process in recommending access to …
NICE turns down BMS’ Opdivo for head and neck cancer
April 11, 2017Manufacturing and Production, Sales and Marketing BMS, NICE, opdivo
Bad news for Bristol-Myers Squibb as NICE chooses not to recommend its immunotherapy drug Opdivo (nivolumab) for use in head …
Immune system influences immunotherapy effectiveness, research shows
April 3, 2017Research and Development, Sales and Marketing immunotherapy, nivolumab, opdivo
Preliminary research conducted at the University of Pittsburgh Cancer Institute (UPCI) has discovered a link between levels of certain immune …
Asia-Pacific NSCLC market to more than double to $6.2bn by 2023
March 21, 2017Manufacturing and Production, Research and Development, Sales and Marketing BMS, Eli Lilly, MSD, NSCLC, Yervoy, keytruda, opdivo
New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific …
NICE recommends against Opdivo for classical Hodgkin lymphoma
March 15, 2017Research and Development, Sales and Marketing BMS, classical Hodgkin Lymphoma, opdivo
The National Institute of Health and Care Excellence (NICE) has released draft guidance provisionally turning down Bristol-Myers Squibb’s Opdivo (nivolumab) …
Immunotherapy: The three major treatments that are changing cancer prognoses
March 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Cancer, MSD, Roche, immunotherapy, keytruda, oncology, opdivo, tecentriq
The promise of Immunotherapy as a game-changer for cancer treatment has been evident since its advent in the space. However, …
The March 2017 issue of Pharmafocus is now live!
February 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, FDA, Johnson & Johnson, MSD, Roche, Trump, crispr, immunotherapy, opdivo
The latest edition of Pharmafocus is available to read online now! From breakthroughs in antibiotic resistance R&D to gene editing …
MSD aims to get the jump on BMS treating bladder cancer
February 6, 2017Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, MSD, keytruda, opdivo
Bristol-Myers Squibb’s Opdivo was only just approved for second-line treatment of bladder cancer, but MSD has attempted to have its …
FDA clears Opdivo to treat most common form of bladder cancer
February 6, 2017Sales and Marketing BMS, Bristol-Myers Squibb, MSD, bladder cancer, immunotherapy, keytruda, opdivo
Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. …
BMS receives $625 million patent settlement boost from Merck
January 23, 2017Sales and Marketing BMS, MSD, Merck, keytruda, opdivo
Bristol-Myers Squibb were in desperate need of releasing good news after the brief announcement that it would no longer be …
